Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery
PADCEV® (enfortumab vedotin-ejfv) Efficacy in Patients with la/mUC
Median overall survival of the patients following all o | Open-i
Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months
Survival Analysis in R
Frontiers | Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research
estimation - Estimating median survival times from Kaplan-Meier plot inspection - Cross Validated
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma | NEJM
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram
Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma | Anticancer Research
Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis | SpringerLink
MARGENZA® Clinical Results
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
Efficacy Results | ONIVYDE® (irinotecan liposome injection) | HCP | Onivyde
Survival (time to event) data: median survival times | The BMJ
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X
